NAD Boosters for Longevity (NMN and NR)

Nicotinamide adenine dinucleotide (NAD+) is an essential coenzyme for over 500 enzymatic reactions and the obligate substrate for sirtuins, PARPs, and CD38. Multiple independent labs have shown that tissue NAD+ falls by roughly 50% between ages 40 and 60 in humans, and that this decline is causally linked to age-related metabolic dysfunction, mitochondrial decay, and impaired DNA repair. Two oral precursors — nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — reliably raise blood NAD+ in humans by 1.5× to 2× at gram doses, and have generated one of the most contested debates in longevity science. This page walks through why NAD declines, how the precursors work, the David Sinclair vs Charles Brenner controversy over NMN versus NR, the controversial Slc12a8 transporter, and what the current human trial evidence actually shows.

Table of Contents

  1. What NAD Does and Why It Matters
  2. Why NAD Declines With Age
  3. CD38 and the NAD Consumers
  4. The Precursor Cascade (Tryptophan to NR to NMN to NAD)
  5. NMN vs NR: The Sinclair-Brenner Debate
  6. The Slc12a8 Transporter Controversy
  7. Human Clinical Trials
  8. Niacin and Nicotinamide as Cheaper Alternatives
  9. Practical Protocol and Cautions
  10. Key Research Papers
  11. Connections

What NAD Does and Why It Matters

NAD+ (oxidized nicotinamide adenine dinucleotide) is the most abundant non-protein redox molecule in living cells. It exists in two forms — oxidized NAD+ and reduced NADH — and shuttles electrons between metabolic reactions. The NAD+/NADH ratio is the central indicator of cellular energy state.

Beyond its role as a redox cofactor, NAD+ is consumed (not just recycled) by three families of enzymes that are central to aging:

  1. Sirtuins (SIRT1–SIRT7): NAD+-dependent deacylases that regulate gene expression, DNA repair, mitochondrial biogenesis, and metabolic flux. Discussed in depth on the Sirtuin Activators page. Sirtuin activity is rate-limited by NAD+ availability.
  2. PARPs (Poly-ADP-Ribose Polymerases): respond to DNA strand breaks by transferring ADP-ribose units from NAD+ onto target proteins. PARP1 alone can consume up to 80% of cellular NAD+ in heavily damaged cells, depleting the pool available for sirtuins and energy metabolism.
  3. CD38 and CD157: NAD+ glycohydrolases originally identified on lymphocyte surfaces but now known to be expressed on many cell types. CD38 activity rises with age and accelerates NAD+ decline.

Loss of NAD+ therefore simultaneously degrades energy metabolism, sirtuin signaling, and DNA repair — three of the hallmarks of aging at once. This is the mechanistic rationale for the NAD-precursor longevity hypothesis: if we can restore NAD+, we can simultaneously restore mitochondrial function, sirtuin activity, and DNA repair capacity.

Back to Table of Contents

Multiple independent measurement methods (mass spectrometry of skin biopsies, NMR of muscle tissue, plasma assays) have converged on the conclusion that NAD+ declines with age. The precise magnitude varies by tissue and measurement method, but a roughly 50% decline in skeletal muscle and brain NAD+ between ages 40 and 60 is consistent across studies.

The decline is driven by three interacting processes:

  1. Reduced synthesis: enzymes in the salvage pathway (NAMPT, NMNAT) decline with age in some tissues, reducing the rate at which nicotinamide is recycled back into NAD+.
  2. Increased consumption by CD38: CD38 expression on tissue-resident macrophages and other cells rises markedly with age, increasing NAD+ glycohydrolase activity in tissue.
  3. Increased PARP activity: cumulative DNA damage with age drives chronic PARP1 activation, which consumes NAD+.

The result is a chronic energy-and-signaling deficit that aligns with the broader pattern of age-related mitochondrial dysfunction. Restoring NAD+ pharmacologically — in mice — has been shown to restore mitochondrial function, improve insulin sensitivity, improve exercise capacity, and partially reverse age-related decline in muscle and brain function. Whether the same effects translate to humans at the doses and timeframes used in clinical trials remains the central open question.

Back to Table of Contents

CD38 and the NAD Consumers

The discovery that CD38 is the dominant age-related NAD+ consumer (Camacho-Pereira et al., Cell Metab 2016) shifted the field. Mice lacking CD38 do not show the age-related NAD+ decline; conversely, CD38 overexpression accelerates NAD+ loss and aging phenotypes. This implies that a CD38 inhibitor could raise NAD+ as effectively as supplementing precursors.

The candidate CD38 inhibitor with the most attention is apigenin, a flavonoid found in parsley, chamomile, celery, and onions. Apigenin inhibits CD38 in vitro and raises NAD+ in mice. Apigenin supplements are now sold by some longevity-focused vendors. Whether apigenin reaches plasma concentrations sufficient to inhibit CD38 in vivo at supplement doses is uncertain. Quercetin is also a CD38 inhibitor at high concentrations. 78c is an experimental CD38 inhibitor with stronger in vitro activity but no human data.

The implication for protocol design is that a comprehensive NAD-restoration strategy might combine precursor supplementation (NR or NMN, to drive synthesis) with CD38 inhibition (apigenin/quercetin, to reduce consumption), although this combined approach has not been rigorously tested in humans.

Back to Table of Contents

The Precursor Cascade (Tryptophan to NR to NMN to NAD)

Cells make NAD+ through multiple parallel routes, all of which converge on the central molecule:

  1. De novo from tryptophan: dietary tryptophan can be converted to NAD+ through an 8-step kynurenine pathway. This is the slowest and least efficient route, but it explains why severe niacin deficiency requires extreme dietary restriction.
  2. From niacin (nicotinic acid): niacin is converted to NAD+ through the Preiss-Handler pathway. This is the route used by therapeutic high-dose niacin for dyslipidemia, and is highly efficient but causes the well-known flush.
  3. From nicotinamide (NAM): NAM enters the salvage pathway via NAMPT (the rate-limiting enzyme) which converts it to NMN, which NMNAT then converts to NAD+. This is the dominant pathway in most tissues most of the time.
  4. From nicotinamide riboside (NR): NR enters cells through nucleoside transporters, gets phosphorylated by NRK1/NRK2 to NMN, and then converted to NAD+ by NMNAT. This route bypasses NAMPT (which is the bottleneck in some tissues).
  5. From nicotinamide mononucleotide (NMN): NMN can be converted directly to NAD+ by NMNAT. But because NMN is a charged phosphate, it generally cannot cross cell membranes directly — the Sinclair lab's claim that a specific NMN transporter (Slc12a8) exists is the subject of the controversy discussed below.

The cascade matters because it determines which oral precursor actually delivers NAD+ to the inside of cells. NR is the most established — Trammell's seminal 2016 Nat Commun paper showed NR is uniquely orally bioavailable. NMN is also orally bioavailable, but Brenner's lab and others have argued that orally administered NMN is mostly converted back to NR (or to nicotinamide) in the gut before entering cells, making it effectively NR by the time it reaches the cell interior. The Sinclair lab's counterargument hinges on the Slc12a8 transporter.

Back to Table of Contents

NMN vs NR: The Sinclair-Brenner Debate

The two leading NAD precursors on the market are nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). They are chemically nearly identical — NMN is NR with an added phosphate group. The longevity supplement market has become deeply tribal about which is better, and the debate maps fairly cleanly onto two academic camps led by two prominent investigators with declared commercial conflicts.

Charles Brenner (City of Hope) discovered NR's role as a vitamin B3 precursor and patents related to it that became the basis for ChromaDex's Niagen product. Brenner's position: NR is the only oral NAD precursor with rigorously characterized pharmacokinetics, NMN is mostly degraded to NR or nicotinamide before absorption, the claimed Slc12a8 NMN transporter findings are flawed, and NMN's marketing premium over NR is not scientifically justified.

David Sinclair (Harvard) is the most prominent academic advocate for NMN and has a financial interest in companies marketing NMN-based products including Tally Health and various supplement brands. Sinclair's position: NMN is endogenously synthesized just before NAD, is one step closer in the salvage pathway, and the Slc12a8 transporter allows NMN to enter cells directly. Sinclair's 2019 Nature Metabolism paper (Grozio et al.) reported identification of Slc12a8 as the NMN transporter.

What the data actually show, fairly read:

The honest summary: at the level of evidence currently available, both NR and NMN raise human blood NAD+ by similar amounts. NR has more mature pharmacokinetic and safety data. NMN has clearer regulatory uncertainty. Neither has been shown in any rigorous trial to extend human lifespan or even to slow biological aging on validated clocks. The choice between them is closer to a tossup than the partisan marketing on both sides suggests.

Back to Table of Contents

The Slc12a8 Transporter Controversy

The Slc12a8 paper (Grozio et al., Nat Metab 2019) reported that mouse small intestine expresses a sodium-dependent NMN transporter encoded by the Slc12a8 gene. The paper claimed that knockdown of Slc12a8 dramatically reduced NMN uptake, and that the transporter was upregulated in conditions of NAD deficiency. The result was hailed by NMN advocates as proof that NMN reaches cells intact.

In 2021, a multi-author rebuttal in Nature Metabolism (which led to an editorial correction) argued that the Grozio data could not be replicated. Independent groups using purified Slc12a8 protein in liposomes failed to detect NMN transport activity. The original Slc12a8 paper was the subject of an extensive Author Correction but was not formally retracted.

The current consensus position among biochemists is that Slc12a8 may or may not transport NMN, but if it does, the activity is not as dramatic as the original paper claimed. Oral NMN reaching cells likely does so primarily through degradation to NR (which uses nucleoside transporters) or to nicotinamide (which crosses membranes freely), with at most a minor direct-NMN component.

What this means in practice: if NMN works as a NAD precursor in humans (and the human blood-NAD evidence suggests it does), the mechanism is probably indirect through conversion to NR or NAM in the gut. The therapeutic effect should therefore be similar to NR at equivalent molar doses.

Back to Table of Contents

Human Clinical Trials

Human trial evidence on NAD precursors falls into three categories.

Pharmacokinetic and safety trials are well-established. Conze et al. (Sci Rep 2019) gave healthy adults 1g/day of Niagen NR for 8 weeks, showed approximately doubled blood NAD+, and reported good safety. Martens et al. (Nat Commun 2018) ran a similar 6-week NR study in healthy middle-aged adults with similar NAD+ elevation. Both established that NR is safe at gram doses and reliably raises blood NAD+.

Clinical biomarker trials are mixed. Martens et al. found that NR lowered systolic blood pressure by 8 mmHg in adults with prehypertension (a clinically meaningful effect). Dollerup et al. (Am J Clin Nutr 2018) gave 2g/day NR to obese insulin-resistant men for 12 weeks and found NO improvement in insulin sensitivity, NO improvement in mitochondrial function, and NO change in body composition — despite confirmed NAD+ elevation. This was one of the most consequential null results in the field. Yoshino et al. (Science 2021) gave 250 mg/day NMN to prediabetic postmenopausal women for 10 weeks and found improved muscle insulin sensitivity but no change in body composition or systemic insulin sensitivity.

Endpoint trials — trials of NR or NMN with clinical disease endpoints or aging biomarkers — are essentially absent. The longest published trial is approximately 6 months. No trial has reported epigenetic clock changes from NR or NMN. No trial has demonstrated reduced mortality, cardiovascular events, or cognitive decline.

The fair summary: NAD precursors are safe at the gram-dose range, reliably raise blood NAD+, may modestly improve specific markers in specific populations (blood pressure in middle-aged adults on NR, muscle insulin sensitivity in prediabetic women on NMN), but have not been shown to deliver the broader healthspan or lifespan effects that the marketing implies. The biological hypothesis is strong; the clinical evidence is thin.

Back to Table of Contents

Niacin and Nicotinamide as Cheaper Alternatives

An underappreciated point is that niacin (nicotinic acid) and nicotinamide (NAM) are also NAD precursors — they cost a fraction of NR or NMN and are widely available as Vitamin B3. The reason the field has nonetheless focused on NR and NMN deserves examination.

Niacin causes the well-known prostaglandin-mediated "niacin flush" at doses above 100 mg, which limits chronic use. It is dramatically effective at raising NAD+ in tissue. The Coenzyme Q10 + niacin + ALCAR combination (the Saraswathy "mitochondrial cocktail") has shown benefits in mitochondrial disease patients. High-dose niacin (1–3 g/day) was historically used for dyslipidemia but fell out of favor when statins took over.

Nicotinamide (NAM) does not cause flushing and is cheap. The concern is that high-dose NAM directly inhibits sirtuins (as a product-inhibition effect of the sirtuin reaction). For this reason, NAM at gram doses may paradoxically reduce sirtuin activity even while raising NAD+. NR avoids this because it enters the salvage pathway downstream of the inhibition point.

The honest cost-benefit analysis: 500 mg/day of immediate-release nicotinic acid, taken at bedtime with an aspirin pre-medication to mute the flush, raises NAD+ comparably to gram-dose NR at perhaps 1/20th the cost. The newer precursors have a marketing premium that is not fully matched by mechanistic advantage.

Back to Table of Contents

Practical Protocol and Cautions

If choosing to supplement an NAD precursor:

Cautions:

  1. Cancer concern: NAD+ supports both sirtuin-mediated tumor suppression AND cellular energy that fuels cancer proliferation. Several animal studies have shown that NR can accelerate growth of established tumors in some models. Anyone with an active cancer diagnosis or recent cancer history should consult oncology before starting NAD precursors.
  2. Liver enzyme elevation: rare, dose-dependent, reversible. Check ALT/AST at baseline and 3 months on gram-dose precursors.
  3. Methylation burden: NAD precursors are ultimately disposed of through methylation (to N-methylnicotinamide), which consumes S-adenosylmethionine. Some practitioners suggest co-supplementing TMG (trimethylglycine, 500–1000 mg) on high-dose NAD precursor protocols, particularly in MTHFR-variant individuals.
  4. Drug interactions: high-dose niacin interacts with statins and blood-pressure drugs. NR and NMN have fewer reported interactions but data are limited.

The fair statement to a patient considering NAD precursors: the biological hypothesis is strong, the human evidence is suggestive in specific subgroups (prehypertension, prediabetes), the cost is meaningful ($30–$60/month for NR; more for NMN), and no rigorous trial has yet demonstrated lifespan or healthspan extension. Reasonable people may choose to supplement on the strength of mechanism; equally reasonable people may wait for endpoint data.

Back to Table of Contents

Key Research Papers

  1. Bieganowski P, Brenner C. Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell 2004; 117:495–502 — PubMed PMID: 15137942
  2. Trammell SAJ et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun 2016; 7:12948 — PubMed PMID: 27721479
  3. Yoshino J et al. Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab 2011; 14:528–536 — PubMed PMID: 21982712
  4. Mills KF et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab 2016; 24:795–806 — PubMed PMID: 28068222
  5. Camacho-Pereira J et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction. Cell Metab 2016; 23:1127–1139 — PubMed PMID: 27304511
  6. Martens CR et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun 2018; 9:1286 — PubMed PMID: 29599478
  7. Dollerup OL et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men. Am J Clin Nutr 2018; 108:343–353 (the null result) — PubMed PMID: 29982303
  8. Grozio A et al. Slc12a8 is a nicotinamide mononucleotide transporter. Nat Metab 2019; 1:47–57 (with subsequent Author Correction) — PubMed PMID: 32694694
  9. Yoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science 2021; 372:1224–1229 — PubMed PMID: 33888596
  10. Conze D et al. Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Sci Rep 2019; 9:9772 — PubMed PMID: 31273258
  11. Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol 2014; 24:464–471 — PubMed PMID: 24786309
  12. Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science 2015; 350:1208–1213 — PubMed PMID: 26785480
  13. Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab 2018; 27:529–547 — PubMed PMID: 29514064
  14. Massudi H et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One 2012; 7:e42357 — PubMed PMID: 22848760
  15. Covarrubias AJ et al. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol 2021; 22:119–141 — PubMed PMID: 33353981

Back to Table of Contents

Connections

Back to Table of Contents